Get the Stockscreener App
506.74
3.07%
-16.07
Pre-market:
506.74
Vertex Pharmaceuticals Inc stock is traded at $506.74, with a volume of 1.16M.
It is down -3.07% in the last 24 hours and down -7.47% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$522.81
Open:
$522.39
24h Volume:
1.16M
Relative Volume:
0.94
Market Cap:
$128.44B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
30.04
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
-2.99%
1M Performance:
-7.47%
6M Performance:
+13.30%
1Y Performance:
+25.37%
1-Day Range:
$505.27
$523.51
1-Week Range:
$505.27
$529.89
52-Week Range:
$400.74
$560.25
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy - PharmaLive
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
Vertex Pharmaceuticals- Still Too Much Emphasis On CF SupremacyI Foresee A Downgrade - Seeking Alpha
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - The Motley Fool
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance
Vertex Pharmaceuticals stock last trades at USD 526.66 on September 28, 2026 - AD HOC NEWS
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating - Moomoo
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - Fortune
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. - Barron's
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals stock tracks kidney pipeline progress - AD HOC NEWS
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - fortune.com
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance
Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com
Allstate, Autozone, Vertex Pharmaceuticals - TradingView
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex reports positive Phase IIb data as it completes enrollment in pivotal AMKD trial - The Pharma Letter
Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - Yahoo Finance
Jefferies raises Vertex stock price target on kidney drug data By Investing.com - Investing.com Canada
Vertex reports results from Phase IIb AMPLIFIED trial for AMKD - Clinical Trials Arena
TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating - Yahoo Finance
What could reshape the outlook for Vertex Pharmaceuticals (NASDAQ:VRTX) now? - Kalkine Media
Vertex Pharma stock gains 3 percent ahead of the open - AD HOC NEWS
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Kidney Pill Shows Broader Promise, Lifting Rival Maze 25% - finance.biggo.com
Vertex Pharmaceuticals Stock Gains On Kidney Drug DataVertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder - Yahoo Finance
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
BMO reiterates Vertex stock rating on positive trial data By Investing.com - Investing.com Canada
Vertex Pharmaceuticals stock gains as inaxaplin data advance - AD HOC NEWS
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial - BioSpace
Vertex’s midstage data amplify kidney disease market opportunity - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria - TradingView
Urine protein fell 42.7% in a kidney trial. Vertex finished enrolling its next study. - Stock Titan
Inside the Vertex Pharmaceuticals (VRTX) Story Reshaping Healthcare Stocks Sentiment - Kalkine Media
Vertex Pharma stock slips 1.55 percent pre-market before the open - ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 11.97% Potential Upside - DirectorsTalk Interviews
Fierce Biotech Layoff Tracker 2026: Novo reveals 4k more employees were laid off; Sionna halves staff - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Jul 02 '26 |
Sale |
524.99 |
1,500 |
787,485 |
45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
3.09%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):